TRICIA WARD: Open Payments
NPI 1295010635 · LONG GROVE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$265 in 14 payments from 8 companies in 2025. Trend: 2023 $410 · 2024 $556 · 2025 $265
Food & beverage: $265
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $56 |
| Alkermes, Inc. | 2 | $52 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: VRAYLAR, REXULTI, Qelbree, ARISTADA, AUSTEDO XR, LYBALVI, TRINTELLIX, INGREZZA.
Industry payments across IL — which companies pay providers there.
